CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure Hydrocephalus
97% of subjects treated (29/30) experienced improvement in clinical symptoms of NPH0 Serious Adverse Events (SAEs) related to the study device or procedure